CLR01 sodium

Overview

CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42 , α-synuclein , IAPP , tau protein and SOD1 . CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Amyotrophic Lateral Sclerosis | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Amyloid-β | Products > Signaling Pathways > α-synuclein | Products > Signaling Pathways > Amylin Receptor | Products > Signaling Pathways > Tau Protein | Products > Signaling Pathways > SOD

Product Information

• Catalog No.: HY-182304
• CAS No.: 1338489-62-5
• Molecular Formula: C42H30Na2O8P2
• Molecular Weight: 770.61
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source